Related Experiment Video

Updated: May 28, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma

Evan J Walker1, Stephen A Rosenberg, Jack R Wands

  • 1Liver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI.

Forum on Immunopathological Diseases and Therapeutics
|October 11, 2011
PubMed

Insights

Hepatocellular carcinoma (HCC) involves reduced RKIP, an inhibitor of the MAPK pathway. Restoring RKIP may block cancer growth and migration, offering a potential therapeutic target for liver cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent and fatal liver cancer.
  • The MAPK signaling pathway is frequently activated in HCC.
  • RKIP acts as a natural inhibitor of the MAPK pathway.

Purpose of the Study:

  • To investigate the role of RKIP in HCC pathogenesis.
  • To explore the mechanisms of RKIP downregulation in HCC.
  • To identify RKIP as a potential therapeutic target for HCC.

Main Methods:

  • Analysis of RKIP expression levels (mRNA and protein) in HCC samples.
  • Investigation of RKIP's effect on MAPK pathway activation, cell proliferation, and migration.
  • Utilizing HCC cell lines (FOCUS) to study RKIP modulation by inhibitors.

Main Results:

  • RKIP expression is significantly reduced in HCC, correlating with MAPK pathway activation.
  • Downregulation of RKIP promotes HCC cell proliferation and migration.
  • RKIP levels can be modulated by mTOR inhibitors, insulin, and proteasome inhibitors in HCC cells.

Conclusions:

  • RKIP downregulation is a key event in HCC development, contributing to pathway activation and tumor progression.
  • Multiple mechanisms regulate RKIP at both mRNA and protein levels in HCC.
  • Restoring RKIP levels presents a promising therapeutic strategy for HCC treatment.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...